Member Info for Che7win

I take it you’re a believer in P140, albeit with the higher dosage and M high responders?

Yes Nolupus,

Campanies do need cash….and as I keep repeating, if they had said we want to ensure we have sufficient cash so we continue as a going concern then the market would have bounced off 6p.

But to roll out a left field drug as the reason, and to say it’s earnings accretive for shareholders is the issue. It also creates uncertainty for the market and doubt on P140.

I have been in communication with the company and they are all going to fixate on this new drug tomorrow…whilst also discussing P140.

I am only here for P140…and I think that’s true for all private shareholders.

Yes Roger,

But it only makes sense if they need cash for working capital….we’re not interested in another drug candidate.

They have confused the messaging from last September now by bringing dilution into then P140 messaging.

Saying that Landstead - which incidentally is not a long term shareholder, more a leach - wanted to give them money is ridiculous and that they looked around for a drug……ridiculous.

Then to say that this adds shareholder value is ridiculous….,anything that dilutes upside from P140 logically would be avoided.

The only logical explanation is that they need to have cash ahead of P140 negotiation.

Should we vote against this at the AGM? This deal with Lanstead still has to be approved…..

Tim is either so dim he didn’t know the market would react to this news like it has, or so clever he is concealing the real intention of the fund raise.

Either way, it’s not a good look. By trying to be clever, he is looking oh so stupid. I don’t buy the reason for the fund raising - anything that dilutes P140 without it being a necessity is the wrong move. Period.

Why did he not say they need money for working capital? Nothing else is viable here.

Oil up $6 overnight

He also said last year that a deal can come at any time…..and he said not just P140…..

“ImmuPharma's lead asset, P140, continues to be the company's utmost priority. CEO Tim McCarthy emphasized that ongoing licensing discussions are highly active and progressing well, with a strong confidence in securing a deal within the current year. This focus remains unwavering, despite the company's recent expansion into other development areas. The objective is to finalize a deal that best serves both the company and the advancement of P140 through its later stages of development, ensuring maximum value for shareholders.”

The question is, will a deal be done? And that depends on what drug companies think of P140, not the weasel words stated yesterday.

I don’t know what to believe, I think the scientists on Friday have to step up, would be best for Tim to go away.

Nopulus,

In that case, why not just say they need to raise money to continue to negotiate from a position of strength?

The P140 drug does seem to be efficacious, especially so now that the dosage strength has been corrected and they have the diagnosis to identify the high responders.

What annoys me about Tim is that he hardly mentioned P140 yesterday, why this sidetrack yesterday when he knows that the only game in town is P140? Why is he not addressing what we want to know…details in current drug negotiations?

Only if upfront cash from P140 deal will be about £30m does this dilution yesterday become shareholder neutral.

LSBM

“Scrodingerscat; on point A – it’s true that Kapiglucagon wasn’t being pushed forward in any public sense until Lanstead came into the picture, but isn’t that essentially what a partnership is for? A third party comes in, sees value, wants to de‑risk and accelerate something that might otherwise sit in the background. And if the company ends up with more assets to offer, doesn’t that ultimately strengthen IMM’s licensing prospects overall, giving them more leverage and more options in future deals?”

No, this isn’t what is happening. What is happening is that the company is diluting P140 deal for existing shareholders by 20% for a new speculative drug. And this is after they said that the P140 deal would have upfront cash and no dilution would happen. Diluting existing shareholders by 20% to raise £6m is not a logical step….

Tim told us last year there could be a deal at any moment, he’s proven to be a very untrustworthy person.

Does Tim own Landstead? That’s the only conclusion I can come to - as this is a 20% P140 backhander.

Either that or P140 isn’t what we thought it was…..but they’re rolling out the chief scientist on Friday again….

It’s a backhander for the 6 previous fundraisings landstead helped keep them solvent with….a backhander before P140 deal is announced.

Https://www.trtworld.com/article/2a59d74606f1

The message is that he’s raised money for an early stage Type 1 diabetes drug, which is a dilutionary move - unless it adds a few hundred million dollars to outlay the binary upside we had with P140.

This fundraising also needs voted through, how many of us are going to vote against? If the deal was done close, they would have raised a smaller amount?

Yes, our leader has told lies.

He said in the roasted video that other pharm were getting $1 billion upfront payments.

If there was any belief in that, then today’s 20% dilution has given away $200m for an $8m fundraising.

Ie. He could be closing up out a deal for $200m less for P140 and not diluting us any more than he has done with today’s deal.

He is not trustworthy on the deal being done, on the no need for dilution as the deal will have cash, so everything he has said is undone by today’s news,

Very. Very pleased with this news. We now have the concern of fundraising out of the way, which was starting to become a concern.

We have two high profile drugs candidates that will be value accretive, it’s clear that both will be positive for the share price.

Note the company directors comments:

“ However, the Directors have an expectation that this new 2026 Lanstead Agreement will yield a net gain due to the expectation of positive news flow and share price appreciation, around the progression of both P140 and Kapiglucagon through their development programs.”

From the Sunday Roast in November:

We will get “best deal terms because they know that they've got that long protected patent life. And if you look at some of

the deals that have been going on in the autoimmune space in the last 2 to 3 years, I mean, these are staggeringly large deals in terms of financial uh terms.

I mean, eye watering. the amount of $1 billion plus deals. And when I say 1 billion, that's the upfront payment, your milestones along the way plus your royalties. Sorry, not not the royalties.

Definitely not the royalties before royalties. Basically, your upfronts and your milestones. Yeah. And the the amount of 1 billion

billion plus dollar deals, I'll get it out in a moment, that have been done in this autoimmune space in the last two or

three years. Uh I mean, we have, you know, a lot of stats on this. The last time I looked it was it was

something like 12 or 13 deals. It's it's increasing even as we speak….}

Level 2 strengthening, likely to rise again soon.